File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation

TitleClinico-pathological correlations and outcomes of <i>de novo</i> glomerular diseases in patients after haematopoietic stem cell transplantation
Authors
Issue Date10-Dec-2022
PublisherOxford University Press
Citation
Clinical Kidney Journal, 2023, v. 16, n. 6, p. 976-984 How to Cite?
Abstract

Background

Various glomerular pathologies have been reported in patients who have undergone haematopoietic stem cell transplantation (HSCT), but the data on clinico-pathological correlations and clinical outcome remain limited.

Methods

We analysed the clinical and histopathological data of patients who had biopsy-proven de novo glomerular diseases after HSCT since 1999.

Results

A total of 2204 patients underwent HSCT during the period 1999–2021, and 31 patients (1.4%) developed de novo glomerular diseases after a mean duration of 2.8 ± 2.7 years after HSCT. Fifteen of these patients (48.4%) had graft-versus-host-disease prior to or concomitant with renal abnormalities. Proteinuria and eGFR at the time of kidney biopsy were 4.1 ± 5.3 g/day and 50.8 ± 25.4 mL/min/1.73 m2, respectively. Kidney histopathologic diagnoses included thrombotic microangiopathy (TMA) (38.7%), membranous nephropathy (MN) (25.8%), mesangial proliferative glomerulonephritis (12.9%), minimal change disease (9.7%), focal segmental glomerulosclerosis (9.7%) and membranoproliferative glomerulonephritis (3.2%). Immunosuppressive treatment was given to patients who presented with nephrotic-range proteinuria and/or acute kidney injury, while renin–angiotensin–aldosterone blockade was given to all patients with proteinuria ≥1 g/day, with complete and partial response rates of 54.8% and 19.4%, respectively. One patient with TMA progressed to end-stage kidney disease after 24 weeks, and two patients, one with TMA and one with MN, (6.4%) progressed to chronic kidney disease (CKD) Stage ≥3. Kidney and patient survival rates were 96.6% and 83.5%, respectively, at 5 years.

Conclusion

De novo glomerular diseases with diverse histopathologic manifestations affect 1.4% of patients after HSCT, and approximately 10% develop progressive CKD.


Persistent Identifierhttp://hdl.handle.net/10722/329052
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.191

 

DC FieldValueLanguage
dc.contributor.authorYap, DYH-
dc.contributor.authorLie, D-
dc.contributor.authorLau, T-
dc.contributor.authorTang, A-
dc.contributor.authorChan, G-
dc.contributor.authorChan, TSY-
dc.contributor.authorSim, J-
dc.contributor.authorLie, AKW-
dc.contributor.authorChan, TM-
dc.date.accessioned2023-08-05T07:54:55Z-
dc.date.available2023-08-05T07:54:55Z-
dc.date.issued2022-12-10-
dc.identifier.citationClinical Kidney Journal, 2023, v. 16, n. 6, p. 976-984-
dc.identifier.issn2048-8505-
dc.identifier.urihttp://hdl.handle.net/10722/329052-
dc.description.abstract<p>Background</p><p>Various glomerular pathologies have been reported in patients who have undergone haematopoietic stem cell transplantation (HSCT), but the data on clinico-pathological correlations and clinical outcome remain limited.</p><p>Methods</p><p>We analysed the clinical and histopathological data of patients who had biopsy-proven <em>de novo</em> glomerular diseases after HSCT since 1999.</p><p>Results</p><p>A total of 2204 patients underwent HSCT during the period 1999–2021, and 31 patients (1.4%) developed <em>de novo</em> glomerular diseases after a mean duration of 2.8 ± 2.7 years after HSCT. Fifteen of these patients (48.4%) had graft-versus-host-disease prior to or concomitant with renal abnormalities. Proteinuria and eGFR at the time of kidney biopsy were 4.1 ± 5.3 g/day and 50.8 ± 25.4 mL/min/1.73 m<sup>2</sup>, respectively. Kidney histopathologic diagnoses included thrombotic microangiopathy (TMA) (38.7%), membranous nephropathy (MN) (25.8%), mesangial proliferative glomerulonephritis (12.9%), minimal change disease (9.7%), focal segmental glomerulosclerosis (9.7%) and membranoproliferative glomerulonephritis (3.2%). Immunosuppressive treatment was given to patients who presented with nephrotic-range proteinuria and/or acute kidney injury, while renin–angiotensin–aldosterone blockade was given to all patients with proteinuria ≥1 g/day, with complete and partial response rates of 54.8% and 19.4%, respectively. One patient with TMA progressed to end-stage kidney disease after 24 weeks, and two patients, one with TMA and one with MN, (6.4%) progressed to chronic kidney disease (CKD) Stage ≥3. Kidney and patient survival rates were 96.6% and 83.5%, respectively, at 5 years.</p><p>Conclusion</p><p><em>De novo</em> glomerular diseases with diverse histopathologic manifestations affect 1.4% of patients after HSCT, and approximately 10% develop progressive CKD.</p>-
dc.languageeng-
dc.publisherOxford University Press-
dc.relation.ispartofClinical Kidney Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleClinico-pathological correlations and outcomes of <i>de novo</i> glomerular diseases in patients after haematopoietic stem cell transplantation-
dc.typeArticle-
dc.identifier.doi10.1093/ckj/sfac264-
dc.identifier.volume16-
dc.identifier.issue6-
dc.identifier.spage976-
dc.identifier.epage984-
dc.identifier.eissn2048-8513-
dc.identifier.issnl2048-8505-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats